PharmaCielo Ltd.
PCLO.V
Toronto Stock Exchange Ventures0.08
CAD
+0.00
- -
ISIN
CA71716K1012
CUSIP
71716K101
Return %
Stock
S&P500
1Y
50.00
26.57
3Y
-64.29
76.60
5Y
-95.13
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Marc Lustig
- Full Time Employees
- 268
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 82 Richmond Street East Toronto ON Canada M5C 1P1
- IPO Date
- Mar 4, 2019
- Website
- pharmacielo.com
- Similar Companies
- Business
- PharmaCielo Ltd. engages in the ethical and sustainable cultivation, processing, and supply of medicinal-grade cannabis products. The company produces medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis, and other related products, alongside telemedicine software solutions. PharmaCielo primarily serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies across multiple global markets, including Canada, Latin America, Africa, and emerging Asian markets. The company operates through its subsidiary PharmaCielo Colombia Holdings S.A.S. and is headquartered in Toronto, Canada. PharmaCielo recently achieved significant sales growth, notably a 143% year-over-year increase resulting in a total revenue of CAD 3.54 million for the fiscal year ending 2024, accompanied by improved gross profit margins and adjusted EBITDA gains due to a more diverse customer base and cost reductions. Key strategic developments include a binding letter of intent to acquire Siam Ventures, a contract manufacturing business based in Thailand, which establishes PharmaCielo’s entry into large Asian markets and broadens its manufacturing capabilities. The company's board will be strengthened by the addition of Siam Ventures' Chairman and CEO post-acquisition. Furthermore, PharmaCielo formed a strategic partnership with Benuvia Operations, LLC to produce current Good Manufacturing Practice (cGMP) and European Union-Good Manufacturing Practice (EU-GMP) pharmaceutical-grade active pharmaceutical ingredients (APIs), enabling expansion into global pharmaceutical markets such as Brazil, Australia, Europe, and the United States. Additional recent operational updates include the completion of the sale of its La Margarita land asset to repay a significant loan and strengthen its balance sheet, allowing focus on high-value sales pipeline expansion. PharmaCielo’s product distribution has extended to 12 countries, including first shipments to Morocco, providing entry into African and broader international markets. Founded in 2014, the company continues to build on its position as a premier global supplier of pharmaceutical-grade cannabis extracts, with ongoing efforts to broaden its product portfolio beyond CBD isolate and to meet increasing global demand for reliable, high-quality medicinal cannabis products.
PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares